Biotech Values

[vinmantoo]

Assets get mispriced all the time. In the long run Jay will be proven right and Jake will be proven wrong. I also said that I believe there is a gulf between what Jay knows the EDP-235 (and access to their follow-on compound) is worth, vs what the market and less informed participants like Jake think it's worth. Jay is not going to screw-over ENTA shareholders by accepting a lowball price.

I think that is why it was an excellent move to monetize some 50% of the HepC revenues. ENTA won't be bargaining for a partnership from a position of weakness like what happened with their HepC drugs and the deal with ABBV.

Speaking of ABBV, the fact that they advanced their own 3CL Covid protease inhibitor into phase I trials shows they have interest in being part of the area of Covid therapeutics. However, their drug has the same drawback as Paxlovid in requiring a drug pump inhibitor. That interest in Covid drugs makes ABBV a potential partner for EDP-235 in my view.